Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | FAP | Q12884 | 3/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | FURIN | P09958 | 4/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170780 | 0.92 | PTGS1 (0.32) | PTGS1PTGS2FAP | |
| SCHEMBL22694922 | 0.91 | FAP (0.37) | PTGS1PTGS2FAPFURINELANE | |
| SCHEMBL18909025 | 0.91 | FAP (0.37) | PTGS1PTGS2FAPFURINELANE | |
| SCHEMBL22267878 | 0.91 | FAP (0.37) | PTGS1PTGS2FAPFURINELANE | |
| SCHEMBL21534475 | 0.90 | SIRT5 (0.34) | FAPAKT1FURINSIRT2SIRT1 | |
| SCHEMBL20935173 | 0.87 | ELANE (0.34) | FAPAKT1FURINELANE | |
| SCHEMBL23436443 | 0.84 | FAP (0.34) | PTGS1PTGS2FAPFURIN | |
| SCHEMBL22668644 | 0.84 | FAP (0.34) | PTGS1PTGS2FAPFURIN | |
| SCHEMBL19681474 | 0.84 | NPY5R (0.39) | PTGS1PTGS2FAPAKT1 | |
| SCHEMBL20340684 | 0.84 | FAP (0.37) | PTGS1PTGS2FAPFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9950076-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | PTGS1 738/4885PTGS2 1278/4885FAP 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.